KLRS logo

KLRSKalaris Therapeutics

$4.36
$0.20
(4.81%)
Today
Closed $4.36
$0.00
(0.00%)
After Hours
Updated: 07:26 PM EDT
Reported EarningsMay 12
Mkt Cap$90.8M
Vol60,023.00

About

Kalaris Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for retinal diseases. It is focusing on developing TH103, a novel anti-VEGF agent targeted at treating neovascular and exudative retinal diseases. The company was founded by Srinivas Akkaraju, Mike Dybbs and Napoleone Ferrara in 2019 and is headquartered in Berkeley Heights, NJ.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
20

Frequently Asked Questions

What is Market Cap of Kalaris Therapeutics Inc.?
What is the 52-week high for Kalaris Therapeutics Inc.?
What is the 52-week low for Kalaris Therapeutics Inc.?
What is Kalaris Therapeutics Inc. stock price today?
What was Kalaris Therapeutics Inc. stock price yesterday?
What is the PE ratio of Kalaris Therapeutics Inc.?
What is the Price-to-Book ratio of Kalaris Therapeutics Inc.?
What is the 50-day moving average of Kalaris Therapeutics Inc.?
How many employees does Kalaris Therapeutics Inc. have?